Article

Current Treatment Options in Cardiovascular Medicine

, Volume 3, Issue 6, pp 493-505

Cardiomyopathy caused by antineoplastic therapies

  • Valeriano C. SimbreIIAffiliated withDivisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
  • , M. Jacob AdamsAffiliated withDivisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
  • , Sampada S. DeshpandeAffiliated withDivisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
  • , Sarah A. DuffyAffiliated withDivisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
  • , Tracie L. MillerAffiliated withDivisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
  • , Steven E. LipshultzAffiliated withDivisions of Cardiology and Gastroenterology/Nutrition, Department of Pediatrics, and Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Opinion statement

The goals of care for patients at risk for cardiomyopathy induced by cancer treatment should include prevention, early diagnosis, treatment of subclinical cardiac dysfunction, prevention of disease progression, and prolongation of patient survival. Any strategy aimed to minimize the cardiotoxic effects of cancer treatment should maintain the treatment’s antineoplastic efficacy. Successful therapy achieves the highest health-related quality of life that is defined by the balance between maximizing the efficacy of oncologic therapy and minimizing the toxicity of this therapy. Doxorubicin-induced cardiotoxicity can be reduced by limiting the overall cumulative dose.

There is no specific treatment for cancer therapy-related cardiomyopathy, and symptomatic patients should receive standard treatments for congestive heart failure such as afterload reduction, beta-blockers, diuresis, and digoxin. Afterload reduction with angiotensin-converting enzyme inhibitors such as enalapril and captopril may be indicated in patients with elevated afterload and asymptomatic left ventricular dysfunction diagnosed by echocardiography. Beta-blockers may improve myocardial systolic dysfunction and may be useful in the treatment of cancer treatment-induced cardiomyopathy.

Cardiac transplantation remains a viable option in patients with cancer treatment-induced end-stage heart disease.